Primary objective: To compare the pharmacokinetic characteristics of flufenidone capsules in subjects with mild hepatic impairment and subjects with normal hepatic function. Secondary objective: To evaluate the safety of flufenidone capsules in subjects with hepatic impairment.

Start Date18 Mar 2022

Sponsor / Collaborator

Haikou Pharmaceutical Co. Ltd.

[+1]

CTR20211557

/ Active, not recruitingPhase 2

以富马酸丙酚替诺福韦片作为基础治疗，评估不同剂量的氟非尼酮胶囊治疗慢性乙型病毒性肝炎肝纤维化的有效性和安全性的多中心、随机、双盲、安慰剂、平行对照 II 期临床试验

[Translation] A multicenter, randomized, double-blind, placebo-controlled, parallel-controlled phase II clinical trial to evaluate the efficacy and safety of different doses of flufenidone capsules in the treatment of liver fibrosis in chronic hepatitis B using tenofovir alafenamide fumarate tablets as the basic treatment

主要目的：与安慰剂对照，初步评价不同剂量氟非尼酮胶囊治疗慢性乙型病毒性肝炎肝纤维化的有效性。次要目的：初步评价不同剂量氟非尼酮胶囊治疗慢性乙型病毒性肝炎肝纤维化的安全性。

[Translation]

Primary objective: To preliminarily evaluate the effectiveness of different doses of flufenidone capsules in the treatment of liver fibrosis caused by chronic hepatitis B virus infection compared with placebo. Secondary objective: To preliminarily evaluate the safety of different doses of flufenidone capsules in the treatment of liver fibrosis caused by chronic hepatitis B virus infection.

Start Date22 Nov 2021

Sponsor / Collaborator

Haikou Pharmaceutical Co. Ltd.

[+1]

CTR20211372

/ CompletedNot Applicable

富马酸丙酚替诺福韦片对氟非尼酮胶囊的药代动力学影响试验

[Translation] Effect of tenofovir alafenamide fumarate tablets on the pharmacokinetics of flufenidone capsules

主要目的：评价富马酸丙酚替诺福韦片对中国健康成人受试者餐后状态下口服氟非尼酮胶囊药代动力学的影响。次要研究目的：评价中国健康成人受试者餐后状态下单独口服氟非尼酮胶囊、随餐单独服用富马酸丙酚替诺福韦片或餐后状态下同时服用富马酸丙酚替诺福韦片和氟非尼酮时的安全性。

[Translation]

Primary objective: To evaluate the effect of tenofovir alafenamide fumarate tablets on the pharmacokinetics of flufenidone capsules in healthy Chinese adult subjects after meals. Secondary objective: To evaluate the safety of flufenidone capsules alone in healthy Chinese adult subjects after meals, taking tenofovir alafenamide fumarate tablets alone with meals, or taking tenofovir alafenamide fumarate tablets and flufenidone at the same time after meals.

Start Date06 Jul 2021

Sponsor / Collaborator

Haikou Pharmaceutical Co. Ltd.

[+1]

100 Clinical Results associated with Fluorofenidone

100 Translational Medicine associated with Fluorofenidone

100 Patents (Medical) associated with Fluorofenidone

Literatures (Medical) associated with Fluorofenidone

01 Nov 2024·Translational Lung Cancer Research

Fluorofenidone enhances cisplatin efficacy in non-small cell lung cancer: a novel approach to inhibiting cancer progression

Article

Author: Jiang, Yupeng ; Wang, Shunjun ; Liu, Guowei ; Zhang, Chenzi ; Marcucci, Fabrizio ; Yu, Laishun

BackgroundNon-small cell lung cancer (NSCLC), the most prevalent lung cancer subtype, presents significant treatment challenges. Cisplatin (CP)-based regimens are central to the treatment of multiple solid tumors, but its use is restricted due to its dose-related renal toxicity. We previously found that fluorofenidone {1-[3-fluorophenyl]-5-methyl-2-[(1H)]-pyridone (AKF-PD)} effectively reverses CP-induced acute kidney injury (AKI). However, it remains unclear whether AKF-PD can synergistically ameliorate NSCLC when used together with CP. Thus, this study sought to investigate the effect of AKF-PD on NSCLC and examined its combinatory use with CP for cancer treatment.MethodsWe conducted cell viability assays, 5-ethynyl-2'-deoxyuridine (EdU) experiments, colony-forming assays, wound-healing tests, and Transwell experiments in A549 and H1299 cells to explore the effects of AKF-PD on NSCLC. We then detected the epithelial-mesenchymal transition (EMT) markers [i.e., epithelial cadherin (E-cadherin), matrix metallopeptidase 9 (MMP9), vimentin, and snail family transcriptional repressor 1 (SNAIL)], phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR), and mitogen-activated protein kinase (MAPK), to identify the potential mechanisms of AKF-PD. Further, via the combined use of AKF-PD and CP, we found that AKF-PD enhanced the antitumor effect of CP, and we suggest that this may be due to its inhibitory effect on EMT. We also examined the effect of combining AKF-PD and CP in other cancer cell lines, including Hela, SiHA, MDA-MB-231, 5-8F, and UM-UC-3 cells.ResultsAKF-PD significantly inhibited the proliferation and invasion of NSCLC cells (A549 and H1299), suppressed the activation of the MAPK and PI3K/AKT/mTOR pathways, and inhibited the EMT of the tumor cells. When AKF-PD was used in combination with CP, these effects were further enhanced. We also found that AKF-PD enhanced the anti-cancer effect of CP in a variety of cancer cell lines, including cervical cancer (Hela cells and SiHA cells), nasopharyngeal cancer (5-8F cells), triple-negative breast cancer (MDA-MB-231 cells), and bladder cancer (UM-UC-3 cells).ConclusionsAKF-PD not only mitigates CP-induced AKI but also enhances the anti-cancer efficacy of CP. Our findings provide valuable insights into the treatment of NSCLC and may have clinical applications.

01 Dec 2023·Cell biochemistry and biophysics

Fluorofenidone Attenuates Renal Interstitial Fibrosis by Enhancing Autophagy and Retaining Mitochondrial Function.

Article

Author: Lu, Miaomiao ; Zhou, Hongli ; Liu, Wenlin ; Xing, Di ; Dong, Haonan

BACKGROUNDFluorofenidone (AKF-PD) is a novel pyridone agent and has potent anti-NLRP3 inflammasome and anti-fibrotic activities. However, the mechanisms underlying its pharmacological actions are not fully understood.METHODSA renal fibrosis rat model was established by the unilateral ureteral obstruction (UUO) procedure and the rats were randomized and treated with, or without, AKF-PD for 3 and 7 days. The levels of renal fibrosis, NLRP3 inflammasome activation, mitochondrial function, and autophagy were tested in rat kidney tissues. Macrophages following lipopolysaccharides (LPS) and adenosine 5'-triphosphate (ATP) stimulation were examined by Western blot, spectrophotometry, and TEM.RESULTSCompared with the untreated UUO rats, AKF-PD treatment significantly mitigated the UUO procedure-induced renal fibrosis in rats. AKF-PD treatment decreased mitochondrial dysfunction and IL-Iβ and caspase-1 expression in rat kidney tissues and reduced mitochondrial reactive oxygen species production in activated macrophages. Mechanistically, AKF-PD treatment significantly attenuated the PI3K/AKT/mTOR signaling, increased Beclin-1 and LC3 II expression and autophagosome formation, and ameliorated the mitochondrial damage in renal tissues and activated macrophages.CONCLUSIONThe results indicated that AKF-PD treatment inhibited renal interstitial fibrosis by regulating the autophagy-mitochondria-NLRP3 inflammasome pathway.

01 Nov 2023·Biochemical and Biophysical Research Communications

Fluorofenidone enhances cardiac contractility by stimulating CICR and CaV1.2

Article

Author: Ávila, Guillermo

Fluorofenidone (AKF-PD) is a novel pyridone derivative that inhibits fibrosis and inflammation in many tissues. Accordingly, it has been effective in disease models, such as liver failure, nephropathy, and pulmonary fibrosis. However, its potential role in cardiac physiology and pathology has yet to be elucidated. Thus, this paper investigated a possible functional impact of AKF-PD on adult rat cardiac myocytes. Cells were kept in culture for 1-2 days under either control conditions or the presence of AKF-PD (500 μM). They were next examined concerning cell contractility, intracellular Ca²⁺ homeostasis, and activity of voltage-gated Ca²⁺ channels. Remarkably, AKF-PD enhanced the percentage of cell shortening and rates of both contraction and relaxation by nearly 100%. A stimulus in Ca²⁺-induced Ca²⁺ release (CICR) most likely accounts for these effects because AKF-PD also increased the magnitude of electrically evoked Ca²⁺ transients. Of note, the compound did not alter the peak value of caffeine-elicited Ca²⁺ transients, indicating stimulation of CICR at constant sarcoplasmic reticulum Ca²⁺ load. Since CICR is triggered by the entry of Ca²⁺ through Ca_V1.2 (I_Ca), a possible effect on these Ca²⁺ channels was also investigated. AKF-PD increased the magnitude of both I_Ca and maximal macroscopic Ca²⁺ conductance (G_max) by about 50%. However, no differences were found in either voltage dependence of inactivation or the amount of maximal immobilization-resistant charge movement (Q_max). Thus, the effect on I_Ca could be explained by a higher channel's open probability (P_o) rather than a greater abundance of channel proteins. Additional data indicate that AKF-PD reduces the rate of Ca²⁺ extrusion in the presence of caffeine, suggesting inhibition of the Na/Ca exchanger. Overall, these results indicate that AKF-PD upregulates the P_o of Ca_V1.2 and then sequentially enhances I_Ca, CICR, and contractility. Therefore, the novel compound is also a candidate to be tested in cardiac disease models.

100 Deals associated with Fluorofenidone

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fibrosis, Liver	Phase 2	CN	Central South University	22 Nov 2021
Fibrosis, Liver	Phase 2	CN	Haikou Pharmaceutical Co. Ltd.	22 Nov 2021
Hepatitis B, Chronic	Phase 2	CN	Haikou Pharmaceutical Co. Ltd.	22 Nov 2021
Hepatitis B, Chronic	Phase 2	CN	Central South University	22 Nov 2021
Renal fibrosis	Phase 1	CN	Hainan Haiyao Co., Ltd.	-
Renal fibrosis	Phase 1	CN	Central South University	-
Renal fibrosis	Phase 1	CN	Dierepharma HK Ltd	-
Liver Cirrhosis	Discovery	CN	Central South University	19 Nov 2018
Liver Cirrhosis	Discovery	CN	Haikou Pharmaceutical Co. Ltd.	19 Nov 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis